pharma news today obesity drugs glp-1 october 2025 How Lilly Reached $1 Trillion: Manufacturing Strategy Behind the Drug Boom Outlook for Obesity in 2026:
Description
Natural GLP-1 Supplement: Struggling with cravings
We and others have shown that GLP-1 drugs reduce risks of many substance use and addiction disorders.
Methods This systematic review was conducted across PubMed/MEDLINE and Web of Science
It is not approved for any of these yet, but the intent is clearly broader metabolic health, not just weight loss
President Trump hailed his deal with pharma companies on GLP-1 drug pricing
This acquisition is aimed at enhancing its portfolio with the addition of Metsera's Next-Generation Obesity Portfolio.
